Wedbush reiterated their outperform rating on shares of Arcus Biosciences (NYSE:RCUS – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $30.00 price objective on the stock.
Several other equities analysts have also recently commented on the stock. Cantor Fitzgerald reissued an overweight rating on shares of Arcus Biosciences in a research report on Friday, July 5th. Truist Financial dropped their target price on shares of Arcus Biosciences from $50.00 to $44.00 and set a buy rating on the stock in a research report on Monday, June 24th. Barclays dropped their target price on shares of Arcus Biosciences from $35.00 to $25.00 and set an overweight rating on the stock in a research report on Monday, July 8th. Finally, Citigroup lifted their target price on shares of Arcus Biosciences from $36.00 to $38.00 and gave the stock a buy rating in a research report on Monday, June 3rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $38.11.
View Our Latest Stock Analysis on RCUS
Arcus Biosciences Stock Up 14.0 %
Arcus Biosciences (NYSE:RCUS – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.02). The business had revenue of $39.00 million during the quarter, compared to the consensus estimate of $26.24 million. Arcus Biosciences had a negative return on equity of 40.98% and a negative net margin of 97.47%. The company’s quarterly revenue was up 34.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.04) EPS. On average, analysts anticipate that Arcus Biosciences will post -3.07 EPS for the current fiscal year.
Institutional Investors Weigh In On Arcus Biosciences
Hedge funds have recently modified their holdings of the stock. GAMMA Investing LLC bought a new stake in shares of Arcus Biosciences in the 4th quarter worth approximately $31,000. Spartan Fund Management Inc. purchased a new stake in shares of Arcus Biosciences during the first quarter worth $38,000. Headlands Technologies LLC purchased a new stake in shares of Arcus Biosciences during the first quarter worth $59,000. Quest Partners LLC purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth $77,000. Finally, Cape Investment Advisory Inc. purchased a new stake in shares of Arcus Biosciences during the fourth quarter worth $77,000. Institutional investors own 92.89% of the company’s stock.
Arcus Biosciences Company Profile
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
See Also
- Five stocks we like better than Arcus Biosciences
- What is the Dow Jones Industrial Average (DJIA)?
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Trading Stocks: RSI and Why it’s Useful
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.